[Radionuclide therapy for neuroendocrine tumours].
Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Rigshospitalet, 2100 København Ø, Denmark. jann.mortensen@rh.regionh.dk
Jann
J
Mortensen
Peter
P
Oturai
Liselotte
L
Højgaard
Ulrich
U
Knigge
Carsten Palnaes
CP
Hansen
Lars
L
Martiný
Palle
P
Rasmussen
Andreas
A
Kjaer
D000075202:Contraindications; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D016896:Treatment Outcome
D009942:Organometallic Compounds; C447941:lutetium Lu 177 dotatate; D015282:Octreotide